Free Trial
NASDAQ:ADPT

Adaptive Biotechnologies (ADPT) Stock Price, News & Analysis

Adaptive Biotechnologies logo
$15.54 +0.37 (+2.41%)
As of 03:50 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

About Adaptive Biotechnologies Stock (NASDAQ:ADPT)

Advanced

Key Stats

Today's Range
$15.21
$15.94
50-Day Range
$10.91
$15.65
52-Week Range
$4.27
$15.94
Volume
1.09 million shs
Average Volume
2.02 million shs
Market Capitalization
$2.37 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$13.56
Consensus Rating
Moderate Buy

Company Overview

Adaptive Biotechnologies Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
59th Percentile Overall Score

ADPT MarketRank™: 

Adaptive Biotechnologies scored higher than 59% of companies evaluated by MarketBeat, and ranked 468th out of 948 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Adaptive Biotechnologies has received a consensus rating of Moderate Buy. The company's average rating score is 2.70, and is based on 8 buy ratings, 1 hold rating, and 1 sell rating.

  • Downside Risk

    Adaptive Biotechnologies has a consensus price target of $13.56, representing about 12.7% downside from its current price of $15.52.

  • Amount of Analyst Coverage

    Adaptive Biotechnologies has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about Adaptive Biotechnologies' stock forecast and price target.
  • Earnings Growth

    Earnings for Adaptive Biotechnologies are expected to grow in the coming year, from ($0.92) to ($0.68) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Adaptive Biotechnologies is -18.95, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Adaptive Biotechnologies is -18.95, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Adaptive Biotechnologies has a P/B Ratio of 11.33. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about Adaptive Biotechnologies' valuation and earnings.
  • Percentage of Shares Shorted

    6.13% of the outstanding shares of Adaptive Biotechnologies have been sold short.
  • Short Interest Ratio / Days to Cover

    Adaptive Biotechnologies has a short interest ratio ("days to cover") of 4.4.
  • Change versus previous month

    Short interest in Adaptive Biotechnologies has recently increased by 10.79%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Adaptive Biotechnologies does not currently pay a dividend.

  • Dividend Growth

    Adaptive Biotechnologies does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    6.13% of the outstanding shares of Adaptive Biotechnologies have been sold short.
  • Short Interest Ratio / Days to Cover

    Adaptive Biotechnologies has a short interest ratio ("days to cover") of 4.4.
  • Change versus previous month

    Short interest in Adaptive Biotechnologies has recently increased by 10.79%, indicating that investor sentiment is decreasing significantly.
  • News Sentiment

    Adaptive Biotechnologies has a news sentiment score of 0.82. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 7 news articles for Adaptive Biotechnologies this week, compared to 6 articles on an average week.
  • Search Interest

    Only 6 people have searched for ADPT on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
  • MarketBeat Follows

    8 people have added Adaptive Biotechnologies to their MarketBeat watchlist in the last 30 days. This is an increase of 167% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Adaptive Biotechnologies insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 6.40% of the stock of Adaptive Biotechnologies is held by insiders.

  • Percentage Held by Institutions

    99.17% of the stock of Adaptive Biotechnologies is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Adaptive Biotechnologies' insider trading history.
Receive ADPT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Adaptive Biotechnologies and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

ADPT Stock News Headlines

Your Bank Account Is No Longer Safe
What If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what the Department of Justice just admitted in court—claiming cash isn't legally your property. What does that mean? It means Washington thinks they can seize, freeze, or drain your accounts—whenever they want.tc pixel
See More Headlines

ADPT Stock Analysis - Frequently Asked Questions

Adaptive Biotechnologies' stock was trading at $5.99 on January 1st, 2025. Since then, ADPT stock has increased by 159.1% and is now trading at $15.5220.

Adaptive Biotechnologies Corporation (NASDAQ:ADPT) issued its quarterly earnings results on Tuesday, August, 5th. The company reported ($0.17) EPS for the quarter, topping the consensus estimate of ($0.24) by $0.07. The business's revenue for the quarter was up 36.3% compared to the same quarter last year.
Read the conference call transcript
.

Adaptive Biotechnologies (ADPT) raised $200 million in an initial public offering on Thursday, June 27th 2019. The company issued 12,500,000 shares at $15.00-$17.00 per share. Goldman Sachs, J.P. Morgan and BofA Merrill Lynch acted as the underwriters for the IPO and Cowen, Guggenheim Securities, William Blair and BTIG were co-managers.

Top institutional shareholders of Adaptive Biotechnologies include Voya Investment Management LLC (0.86%), Assenagon Asset Management S.A. (0.03%) and Sound Income Strategies LLC. Insiders that own company stock include Chad M Robins, Harlan S Robins, Julie Rubinstein, Tycho Peterson, Francis Lo, Kyle Piskel, Nitin Sood, Peter M Neupert, R Mark Adams, Stacy L Taylor, Robert Hershberg and Michelle Renee Griffin.
View institutional ownership trends
.

Shares of ADPT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Adaptive Biotechnologies investors own include American Water Works (AWK), Humana (HUM), Voyager Therapeutics (VYGR), Waste Connections (WCN), The RMR Group (RMR), DiamondRock Hospitality (DRH) and AUO (AUOTY).

Company Calendar

Last Earnings
8/05/2025
Today
10/13/2025
Next Earnings (Estimated)
11/06/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:ADPT
CIK
1478320
Employees
790
Year Founded
2009

Price Target and Rating

High Price Target
$20.00
Low Price Target
$9.00
Potential Upside/Downside
-12.8%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.70
Research Coverage
10 Analysts

Profitability

EPS (Trailing Twelve Months)
($0.82)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$159.49 million
Net Margins
-59.07%
Pretax Margin
-59.08%
Return on Equity
-60.93%
Return on Assets
-23.03%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
2.84
Quick Ratio
2.75

Sales & Book Value

Annual Sales
$205.22 million
Price / Sales
11.26
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$1.37 per share
Price / Book
11.07

Miscellaneous

Outstanding Shares
152,274,000
Free Float
142,528,000
Market Cap
$2.31 billion
Optionable
Optionable
Beta
2.06

Social Links

The 10 Best AI Stocks to Own in 2025 Cover

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

This page (NASDAQ:ADPT) was last updated on 10/13/2025 by MarketBeat.com Staff
From Our Partners